company background image
TLMD

SOC TelemedNasdaqGS:TLMD Stock Report

Last Price

US$0.78

Market Cap

US$78.9m

7D

-27.0%

1Y

-89.1%

Updated

19 Jan, 2022

Data

Company Financials +
TLMD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TLMD Stock Overview

SOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States.

SOC Telemed Competitors

Oak Street Health

NYSE:OSH

US$4.9b

1Life Healthcare

NasdaqGS:ONEM

US$2.1b

Accolade

NasdaqGS:ACCD

US$1.2b

Talkspace

NasdaqGS:TALK

US$237.6m

Price History & Performance

Summary of all time highs, changes and price drops for SOC Telemed
Historical stock prices
Current Share PriceUS$0.78
52 Week HighUS$9.48
52 Week LowUS$0.78
Beta0
1 Month Change-48.07%
3 Month Change-60.92%
1 Year Change-89.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-92.18%

Recent News & Updates

Dec 20

SOC Telemed: Virtual Acute Care Niche

SOC Telemed has installed a new management team specifically aiming to reignite growth, but is at least two years away from positive EBITDA. Demographic trends in the United States will exacerbate the problem of matching supply to demand in health care services, and telehealth helps restore some balance. Deep losses in share value over the last year are in line with others in the sector, yet its valuation metrics are beneath its telemedicine and healthcare software services peers.

Aug 25

SOC Telemed: A Pause In Growth

The trends in delivering telehealth continue to expand, with telemedicine encounters remaining at an elevated level relative to pre Covid-19 comparisons. SOC Telemed was a high-growth prospective due to its acquisition of Access Physicians, but the degree of growth has been limited as the delta variant impacts hospitals. The decrease in valuation as a result of its reduced guidance for the rest of 2021 presents a potential entry point for those with a long-term horizon of two-plus years.

Shareholder Returns

TLMDUS HealthcareUS Market
7D-27.0%-3.1%-3.5%
1Y-89.1%13.9%10.2%

Return vs Industry: TLMD underperformed the US Healthcare industry which returned 13.9% over the past year.

Return vs Market: TLMD underperformed the US Market which returned 10.2% over the past year.

Price Volatility

Is TLMD's price volatile compared to industry and market?
TLMD volatility
TLMD Average Weekly Movement17.1%
Healthcare Industry Average Movement8.0%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: TLMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: TLMD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2004226Chris Gallagherhttps://www.soctelemed.com

SOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company’s technology platform, Telemed IQ, provides telemedicine programs. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, and teleICU.

SOC Telemed Fundamentals Summary

How do SOC Telemed's earnings and revenue compare to its market cap?
TLMD fundamental statistics
Market CapUS$78.86m
Earnings (TTM)-US$153.78m
Revenue (TTM)US$80.97m

1.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLMD income statement (TTM)
RevenueUS$80.97m
Cost of RevenueUS$54.58m
Gross ProfitUS$26.39m
ExpensesUS$180.17m
Earnings-US$153.78m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.52
Gross Margin32.59%
Net Profit Margin-189.93%
Debt/Equity Ratio41.5%

How did TLMD perform over the long term?

See historical performance and comparison

Valuation

Is SOC Telemed undervalued compared to its fair value and its price relative to the market?

0.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TLMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TLMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TLMD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: TLMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLMD is good value based on its PB Ratio (0.4x) compared to the US Healthcare industry average (2.6x).


Future Growth

How is SOC Telemed forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

19.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLMD's revenue (23.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: TLMD's revenue (23.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLMD is forecast to be unprofitable in 3 years.


Past Performance

How has SOC Telemed performed over the past 5 years?

-302.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TLMD is currently unprofitable.

Growing Profit Margin: TLMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TLMD's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TLMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).


Return on Equity

High ROE: TLMD has a negative Return on Equity (-35.06%), as it is currently unprofitable.


Financial Health

How is SOC Telemed's financial position?


Financial Position Analysis

Short Term Liabilities: TLMD's short term assets ($57.8M) exceed its short term liabilities ($17.4M).

Long Term Liabilities: TLMD's short term assets ($57.8M) do not cover its long term liabilities ($78.0M).


Debt to Equity History and Analysis

Debt Level: TLMD's net debt to equity ratio (20.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TLMD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TLMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 41% each year.


Dividend

What is SOC Telemed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Chris Gallagher (42 yo)

0.83

Tenure

Dr. Christopher M. Gallagher, M.D., FACC, also known as Chris, is a Director at SOC Telemed, Inc. since March 2021 and serves its Chief Executive Officer since September 1, 2021. He serves as Chief Executi...


Leadership Team

Experienced Management: TLMD's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: TLMD's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.4%.


Top Shareholders

Company Information

SOC Telemed, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: SOC Telemed, Inc.
  • Ticker: TLMD
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$78.858m
  • Shares outstanding: 100.89m
  • Website: https://www.soctelemed.com

Number of Employees


Location

  • SOC Telemed, Inc.
  • 1768 Business Center Drive
  • Suite100
  • Reston
  • Virginia
  • 20190
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 00:07
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.